Sep 14, 2022
Oncotelic Presenting Data for OT101 Against Diffuse Intrinsic Pontine Glioma (DIPG) at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting
Aug 22, 2022
ONCOTELIC REPORTS Q2 2022 COMPARED TO Q2 2021 FINANCIAL RESULTS
Aug 17, 2022
Oncotelic Participating at Biotechgate Digital Partnering
Jul 12, 2022
Oncotelic Announces Presentation of P001- OT-101 Phase 1/2 Trial in Pancreatic Cancer
Jun 15, 2022
Oncotelic Provides Update on OT-101 at the 2022 BIO International Convention
May 25, 2022
Oncotelic Therapeutics Receives FDA Clearance for Phase 2 Clinical Trial of OT-101/Pembroluzimab Combination for Mesothelioma (M201)
May 23, 2022
ONCOTELIC PROVIDES Q1 2022 FINANCIAL RESULTS COMPARED TO Q1 2021, PRODUCT DEVELOPMENT INITIATIVES AND CORPORATE UPDATE
May 18, 2022
Oncotelic Announces Pipeline Presentation and IPO Update of Sapu Therapeutics at the 2022 BIO International Convention
May 11, 2022
ONCOTELIC ANNOUNCES US PATENT GRANT FOR CA4P AND OXI4503 COMBINATION WITH CHECKPOINT INHIBITORS
May 04, 2022
Oncotelic Appoints Seymour Fein M.D. as Chief Regulatory Officer
1
2
3
4
5
6
7
8
9
<<
<
>
>>
Copyright © 2021 Oncotelic Inc., a TGF ImmunoOncology Company. All rights reserved.
Privacy